STANLEY P. KUTCHER, M.D., EDITOR
Tim Yates, B.S.C., M.D.C.M., F.R.C.P.
• Clinically Useful Approaches
Atomoxetine (ATX) is a selective norepinephrine (NE) reuptake inhibitor that was
for the Atypical Antipsychotics
approved as a treatment for ADHD in the United States in November 2002. It was
Antipsychotics) in Pediatric
launched there in January 2003: Its approval and launch in Canada is pending.
What is of particular interest about ATX is that it has a 24–hour effect on ADHD
signs and symptoms (albeit diminishing gradually towards the following morning)on a once–daily morning dosing schedule. Unlike the psychostimulants it is not a
controlled substance, it is less likely to cause insomnia in children and it does not
• Fluoxetine and CBT in
Generalized Social Anxiety
• Paroxetine in Children and
Adolescents With Social
Studies of ATX using the ADHD Rating Scale (ADHD RS), the Conners Parent
Rating Scale–Revised (CPRS–R) and other validated ADHD measures have shown
• Olanzapine in Schizotypal
a beneficial clinical effect on the signs and symptoms of ADHD significantly greater
than placebo and similar to those of IR–MPH. Of these eight studies five were ran-
• Treatment–Emergent Mania in
domized and placebo–controlled while three were open–label including the com-
parison with MPH. There have been no negative trials to date.
ATX is equally effective against inattention and hyperactivity/impulsivity. This
clinical effect has been demonstrated in children, adolescents and adults; withADHD alone and with a range of comorbidities.
In children and adolescents, teachers and parents were in agreement about the
diminution of ADHD–related problems. In the classroom, teachers rated ATX as
Abstracts from the Canadian
24th Annual Conference,
improving childrens’ functioning irrespective of comorbid ODD or LD and prior
Canadian Academy of Child
stimulant response. Conners CGI scores were significantly improved while ratings of
and Adolescent Psychiatry
academic performance (APRS, p
= .106), social skills (SSRS–T, p
= .196), and prob-lem behavior (p
=.025) each showed some improvement.
Beyond the first–line criteria for ADHD, ATX has proven superior to placebo in
improving CHQ measures of self–esteem, psychosocial functioning, parent impactand family activity. The improvements in family–related parameters are linked toATX’s continuing effect into the evening.
Child & Adolescent Psychopharmacology News
is an independent publication that accepts noadvertising or other outside support.
CAPN • 1
pregelatinized starch and dimethicone.
Stanley P. Kutcher, M.D., Editor
Mina K. Dulcan
ability in the rate of its breakdown. Five
so–called “slow” or “poor” metabolizers
“extensive metabolizers” or EMs. In the
Washington University School of Medicine,
serum half–life is about 5 hours. In the
Rachel G. Klein
James T. McCracken
abruptly; no tapering of dose is required.
John Hopkins Medical Institute, Baltimore, MD
Child & Adolescent Psychopharmacology News
(ISSN 1085-0295) is published eight times per year
(Feb, Mar, May, June, Aug, Sept, Nov, and Dec) by
The Guilford Press, 72 Spring Street, New York, NY
10012. Periodicals postage paid at New York, NY, and
SUBSCRIPTION PRICE: Volume 9, 2004 (eight
issues) Individuals $150.00 ($160.00, Canada and for-eign) and Institutions, $225.00 ($235.00, Canada and
foreign). Orders by MasterCard, VISA, or American
Express can be placed by phone at 800-365-7006, Fax212-966-6708, or E-mail [email protected]
; in New
York, 212-431-9800. Payment must be made in U.S.
dollars through a U.S. bank. All prices quoted in U.S.
dollars. Pro forma invoices issued upon request.
Visit our website at www.guilford.com.
Guilford’s GST registration number: 137401014
CHANGE OF ADDRESS: Please inform publisher
at least six weeks prior to move. Enclose mailing label
mg/Kg. This is increased after 3–4 days
with change of address. Claims for lost issues cannot
to 1.2 mg/Kg. After 2–4 weeks if an in-
be honored four months after mailing date. Duplicatecopies cannot be sent to replace issues not delivered
because of failure to notify publisher of change of ad-dress. Postmaster: Send address changes to Child &
Adolescent Psychopharmacology News, Guilford
Press, 72 Spring Street, New York, NY 10012.
Photocopying of this newsletter is not permitted.
This publication is intended to provide accurate and
authoritative information regarding the subject matter
covered. It is sold with the understanding that the pub-
lisher is not engaged in rendering medical, psychologi-
cal, financial, legal, or other professional services.
The recommended doses of medications cited in
this newsletter are not meant to serve as a guide for
prescribing of medications.
Physicians, please check the manufacturer’s product
information sheet or the PHYSICIAN’S DESK REF-
ERENCE for further information and contraindica-
the evening and the following morning.
significant clinical benefit beginning at
CAPN • 2
different titration strategies, different
populations, different cut–offs for in-
plaints were about anorexia (24% vs.
magnitude of this effect is, to a degree,
nolence, fatigue, sedation, dizziness) at
ritability, aggression, emotional distur-
monoamine levels than 1 mg/Kg doses.
tis has been reported quite frequently in
be the result of a highly specific inhibi-
lowers the risk of drug–activated move-
lence and “asthenia”, and GI–related
pus striatum (a pleasure/reward area) its
diarrhea. In dose–response study the in-
sion. This latter point is buttressed by a
CAPN • 3
etc. A few did so because of lack of effi-
dysregulation syndrome” that falls short
non–significanly to be in higher dosage
Safety and Tolerability
medication is very likely to be effective
of tics; in some children their tics were
although not to a level of statistical sig-
subjects by week 8 there was a slight in-
and erectile dysfunction (10% vs. 1%).
if some other mechanism was at work.
Brown University Child and Adolescent
a consultation let-
risk of mydriasis and its use is not rec-
urticaria, and rash have been noted.
years. Clearly there is a long–term ef-
tures for several days before returning to
to overdose with ATX alone. In ‘pure’
the velocity of growth over the first six
where the patient was also taking ATX.
from the baseline height and weight.
CAPN • 4
With Attention-Deficit/Hyperactivity Disor-der: A randomized, Placebo-Controlled,
Dose-Response Study. Pediatrics, 108
Girls With Attention-Deficit/Hyperactivity
Disorder. Pediatrics, 110
Adolescents With Attention-Deficit/Hyper-
Bymaster, F.P. (2002). Atomoxetine Increases
Extracellular Levels of Norepinephrine and
cebo-Controlled Study. American Journal of
Dopamine in Prefrontal cortex of Rat: A Po-
, 11, 1896-1901.
tential Mechanism for Efficacy in Attention
Michelson, D. et al. (2003). Atomoxetine in
Neuropsychopharmacology, 27( 5),
cebo-Controlled Studies,( Biological Psychia-
Bymaster, F.P. et al. (2003). Atomoxetine, A
Newcorn, J. (2003). The Brown University Child
Noradrenergic Neurotransmission. Neurosci-
and Adolescent Pharmacology Update, 5
ence Research division, Lilly Research Labo-
Atomoxetine, ADIS Drug profile, Adis Inter-
national Inc., Yardley PA. Pediatric Drugs,
Atomoxetine Increases Extracellular Levels of
Norepinephrine and Dopamine in Prefrontal
Spencer, T. et al. (2001). An Open-Label,
Cortex of Rat: A Potential Mechanism for Ef-
Dose-Ranging Study of Atomoxetine in Chil-
ficacy in Attention Deficit Hyperactivity Dis-
dren With Attention-Deficit/Hyperactivity
order. Presented at the Canadian College of
Disorder. Journal of Child and Adolescent
Psychopharmacology News, 11
Spencer, T. et al. (2002). Results From 2
Heil, S.H. et al. (2002). Comparison of the sub-
Proof-of-Concept, Placebo-Controlled Stud-
jective, physiological, and psychomotor ef-
ies of Atomoxetine in Children With Atten-
fects of atomoxetine and methylphenidate in
tion-Deficit/Hyperactivity Disorder. Journal of
light drug users. Drug and Alcohol Dependence
Clinical Psychiatry, 63
Atomoxetine on Growth in Children and Ad-
olescents with ADHD. Presented at The Eu-
uous Symptom Relief. Lilly Research Labora-
Psychiatry (ESCAP), Paris, Sept. 28-Oct. 1,
Kratchovil, C.J. et al. (2002). Atomoxetine and
Weiss, M., Tannock, R. et al. Controlled Study of
Once-Daily Atomoxetine in the School Set-
accounts for much of its popularity.
Open-Label Trial. Journal of American Acad-
ting. Presented at the Canadian College of
emy of Child and Adolescent Psychiatry, 41
McCracken, J.T., Sallee, F.R., Leonard, H.L., et
Wernicke, J.F., & Kratochvil, C.J. (2003). Safety
Profile of Atomoxetine in the Treatment of
in children with tic disorders. Poster at
Children and Adolescents With ADHD. Jour-
Dr. Tim Yates is an Associate Professor of Psy-
nal of Clinical Psychiatry, 63
chiatry and Pediatrics, Faculty of Medicine,
atomoxetine for ADHD. The Brown Univer-
University of Calgary, Alberta, Canada.
sity Child and Adolescent Pharmacology Update,
cents with Attention Deficit Hyperactivity
E-mail: [email protected]
Disorder. Journal of Child and Adolescent
Michelson, D. et al. (2001). Atomoxetine in the
Psychopharmacology News, 13
Visit our website at www.guilford.com
to learn more about our publishing program. Search the site by title,
author/editor, or keyword to get complete information on resources not described in our catalog—including
tables of contents and excerpts from reviews. You may also request additional catalogs, exam copies of books,
and periodical samples, as well as subscribe to e-mail lists to receive early notice on releases in your field.
CAPN • 5
P.M.& E. PROJECT MANAGEMENT & ENGINEERING s.r.l. Quinta Edizione del Corso di aggiornamento LA GESTIONE INDUSTRIALE DEL CONTENZIOSO Giovedì 15/marzo LO SCENARIO LEGISLATIVO ED IL SETTORE DELLE COSTRUZIONI 1) Lo scenario legislativo prima della Legge 109/1994 2) La crisi del settore delle costruzioni 1992 3) L’avvento delle norme comunitarie / Le gare eu
Coping With Grief Part II: Loss Through Divorce In Part I we discussed loss through death. This issue focus on coping with grief as a result ofseparation or divorce. Individuals facing marital separation and eventual divorce undergo similar stages described in Part 1. However, the emotional experience may differ in terms of frequency and intensity. The spouse whohas lost her loved one is